T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.

Researchers sought to determine whether combination venetoclax and pegcrisantaspase would be effective in patients with AML.

At AdventHealth East Florida Division, 100% of graduate nurses in its residency program remained with the organization after one year in 2024. For Michele Goeb-Burkett, MSN, RN, senior vice president ...

Nicole Hurley has an extra special memory to hold onto forever. During Friday's University of South Carolina's graduation, in ...

Many men with metastatic hormone-sensitive prostate cancer have not received recommended first-line therapies due to clinicians’ unfamiliarity with treatment guidelines and misinformation about ...

Pediatric patients with high-risk neuroblastoma had significantly lower 5-year survival rates in induction and/or ...

UnityPoint Health celebrated the expansion of the Cancer Center in Moline. The work renovated more than 10,000 square feet of ...

Trinity officials said the $14 million project will better serve the growing number of patients requiring cancer care in the ...

A new study finds that using the ISBAR communication model significantly improves bedside care quality among rheumatology and ...

Johnson & Johnson has generated evidence that the pace of oncology innovation is overwhelming physicians. | Johnson & Johnson ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

During a May 6 meeting hosted by the National Comprehensive Cancer Network (NCCN), stakeholders discussed hindrances to ...